112 results on '"Touw, Daan J"'
Search Results
2. Use of Salivary Iodine Concentrations to Estimate the Iodine Status of Adults in Clinical Practice.
- Author
-
Dekker, Bernadette L, Touw, Daan J, van der Horst-Schrivers, Anouk N A, Vos, Michel J, Links, Thera P, Dijck-Brouwer, D A Janneke, Kobold, Anneke C Muller, and van der Horst-Schrivers, Anouk N A
- Subjects
- *
SALIVA , *IODINE , *FOOD consumption , *SALIVARY proteins , *SALIVARY glands , *ADULTS , *RESEARCH , *THYROID gland tumors , *EVALUATION research , *COMPARATIVE studies , *NUTRITIONAL status - Abstract
Background: Measurement of the 24-h urinary iodine concentration or urinary iodine excretion (UIE) is the gold standard to determine iodine status; however, this method is inconvenient. The use of salivary iodine could be a possible alternative since salivary glands express the sodium-iodine symporter.Objectives: We aimed to establish the correlation between the salivary iodine secretion and UIE, to evaluate the clinical applicability of the iodine saliva measurement.Methods: We collected 24-h urine and saliva samples from 40 participants ≥18 y: 20 healthy volunteers with no specific diet (group 1), 10 patients with differentiated thyroid cancer with a low dietary intake (<50 μg/d, group 2), and 10 patients with a high iodine status as the result of the use of amiodarone (group 3). Urinary and salivary iodine were measured using a validated inductively coupled plasma MS method. To correct for differences in water content, the salivary iodine concentration (SIC) was corrected for salivary protein and urea concentrations (SI/SP and SI/SU, respectively). The intra- and inter-individual CVs were calculated, and the Kruskal-Wallis test and Spearman's correlation were used.Results: The intra-individual CVs for SIC, SI/SP, and SI/SU were 63.8%, 37.7%, and 26.9%, respectively. The inter-individual CVs for SIC, SI/SP, and SI/SU were 77.5%, 41.6% and 47.0%, respectively. We found significant differences (P < 0.01) in urinary and salivary iodine concentrations between all groups [the 24-h UIE values were 176 μg/d (IQR, 96.1-213 μg/d), 26.0 μg/d (IQR, 22.0-37.0 μg/d), and 10.0*103 μg/d (IQR, 7.57*103-11.4*103 μg/d) in groups 1-3, respectively; the SIC values were 136 μg/L (IQR, 86.3-308 μg/L), 71.5 μg/L (IQR, 29.5-94.5 μg/L), and 14.3*103 μg/L (IQR, 10.6*103-25.6*103 μg/L) in groups 1-3, respectively]. Correlations between the 24-h UIE and SIC, SI/SP, and SI/SU values were strong (ρ = 0.80, ρ = 0.90, and ρ = 0.86, respectively; P < 0.01).Conclusions: Strong correlations were found between salivary and urinary iodine in adults with different daily iodine intakes. A salivary iodine measurement can be performed to assess the total iodine body pool, with the recommendation to correct for salivary protein or urea. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models.
- Author
-
Heikal, Omnia Salah, van Rheenen, Patrick F., Touw, Daan J., Kosterink, Jos G. W., Maurer, Marina, Koomen, Jeroen V., Chelle, Pierre, and Mian, Paola
- Subjects
- *
INFLAMMATORY bowel diseases , *PHARMACOKINETICS , *INFLIXIMAB , *NECROSIS , *PEDIATRICS - Abstract
Aims: Use of infliximab (IFX) has improved outcomes in children with inflammatory bowel disease (IBD). However, a proportion of patients does not respond to IFX or loses response over time. Population pharmacokinetic (PopPK) modelling is a promising approach for IFX dose optimization, but with the increasing number of PopPK models in literature, model evaluation is essential. The aims of this study are: (i) to validate the predictive performance of existing IFX PopPK models using a cohort of children with IBD; and (ii) to perform a Bayesian estimation of the most suitable model to predict the next IFX concentrations. Methods: PubMed was searched for IFX PopPK models in children. Selected models were rebuilt and analysed using R. Model performance was assessed through goodness‐of‐fit‐plots, residuals against time, prediction error and prediction‐corrected visual predictive checks. The validation cohort consisted of 73 children with IBD who were treated with IFX in our centre between 2017 and 2023 (340 IFX measurements). Results: We identified 9 PopPK models. Model bias for individual predicted values ranged from −9.29% to 8.01% compared to bias for population predicted values. The model by Vande Casteele et al. demonstrated superior performance (individual predicted bias 2.13, population predicted bias −6.11); upon Bayesian estimation, it predicted induction trough levels with median error of 12.95% but had a median error of −69% predicting maintenance concentrations. Conclusion: The model by Vande Casteele et al. displayed superior performance in initial evaluations but had a high error in estimating next IFX levels and can only be used in practice to predict induction levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. User Acceptability and Technical Robustness Evaluation of a Novel Smart Pill Bottle Prototype Designed to Support Medication Adherence.
- Author
-
Zijp, Tanja R, Touw, Daan J, and Boven, Job FM van
- Subjects
- *
PATIENT compliance , *NOOTROPIC agents , *BOTTLE design , *MEDICAL personnel , *DRUG utilization - Abstract
Purpose: Smart medication adherence monitoring devices can provide objective and granular drug utilization data and help patients engaging with their treatment. In this proof-of-concept study, the acceptability and technical robustness of a novel smart pill bottle prototype (SPBP) were assessed in order to allow further optimization. Methods: The SPBP is an app-controlled automatic dispense system, capturing real-time data on a web-based platform, which sends text reminders and measures storage conditions. A heterogeneous group of ten volunteers was asked to dispense placebo capsules with the SPBP and to follow a predefined dosing schedule for a trial period of 2 weeks. Afterwards, a questionnaire was filled out during a short interview. Primary outcome was dispense adherence as measured by the bottle. Other study outcomes included system acceptability (System Usability Scale [SUS]), self-reported adherence (MARS) and technical robustness of the bottle's mechanics (electronic pill dispenser) and sensors (bottle temperature). Results: The overall dispense adherence rate as measured by the SPBP was 88%. All participants completed the study and four participants had an adherence rate of 100% during the study. The dispense adherence rates corresponded well with participants' self-reported adherence with an average MARS total score of 23.6 (out of 25). Participants judged the system easy to use, with a mean SUS score of 79.3 (range: 57.5– 97.5). The overall mean temperature difference between the bottle sensor and calibrated external sensor was − 0.82°C (range: − 1.37°C to − 0.21°C). Conclusion: The SPBP was well accepted and this study provides data for further optimization and follow-up studies. Smart adherence technologies such as these may change the way healthcare professionals, trialists and patients manage medication adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Authors' reply to amanita intoxication.
- Author
-
Dekkers, Bart G. J. and Touw, Daan J.
- Subjects
- *
TREATMENT effectiveness - Abstract
Dear Editor, We thank our colleagues, Neuschwander-Tetri and Scalzo [[1]], for pointing to biliary drainage as a potentially life-saving treatment option in I Amanita i intoxication [[2]]. In addition to this option, multiple-dose activated charcoal is also a well-recognized method of interrupting the enterohepatic circulation of amatoxins [[3]]. For ethical reasons, however, performing a randomized controlled trial to study the effectiveness of treatments in intoxications may not be possible. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
6. Pharmacokinetics of Tacrolimus in Pregnant Solid‐Organ Transplant Recipients: A Retrospective Study.
- Author
-
Versluis, Jorn, Bourgonje, Arno R., Touw, Daan J., Meinderts, Jildau R., Prins, Jelmer R., de Jong, Margriet F. C., and Mian, Paola
- Subjects
- *
KIDNEY transplantation , *PATIENTS , *TRANSPLANTATION of organs, tissues, etc. , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *TACROLIMUS , *REGRESSION analysis , *LIVER transplantation , *PREGNANCY - Abstract
Data on the pharmacokinetics of tacrolimus during pregnancy are limited. Therefore, the aim of this retrospective study was to characterize the whole‐blood pharmacokinetics of tacrolimus throughout pregnancy. In this single‐center retrospective cohort study, whole‐blood tacrolimus trough concentrations corrected for the dose (concentration‐to‐dose [C/D] ratios) were compared before, monthly during, and after pregnancy in kidney, liver, and lung transplant recipients who became pregnant and gave birth between 2000 and 2022. Descriptive statistics and linear mixed models were used to characterize changes in tacrolimus C/D ratios before, during, and after pregnancy. The total study population included 46 pregnancies (31 pregnant women). Nineteen, 21, and 6 pregnancies were following kidney, liver, and lung transplantation, respectively. Immediate‐release or extended‐release formulations were used in 54.5% and 45.5% of the women, respectively. Tacrolimus C/D ratios significantly (P <.001) decreased (−48%) compared to the prepregnancy state at 7 months of pregnancy. These ratios recovered within 3 months postpartum (P =.002). C/D ratios tended to be lower during treatment with an extended‐release formulation than with an immediate‐release formulation (P =.071). Transplantation type did not significantly affect C/D ratios during pregnancy (P =.873). In conclusion, we found that tacrolimus whole‐blood pharmacokinetics change throughout pregnancy, with the lowest C/D ratios (48% decrease) in the 7th month of pregnancy. In general, the decrease in C/D ratios seems to stabilize from month 4 onward compared to prepregnancy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Placenta-on-a-Chip as an In Vitro Approach to Evaluate the Physiological and Structural Characteristics of the Human Placental Barrier upon Drug Exposure: A Systematic Review.
- Author
-
Elzinga, Femke A., Khalili, Behrad, Touw, Daan J., Prins, Jelmer R., Olinga, Peter, Leuvenink, Henri G. D., van Goor, Harry, Gordijn, Sanne J., Nagelkerke, Anika, and Mian, Paola
- Subjects
- *
PRENATAL drug exposure , *PLACENTA , *MICROFLUIDIC devices , *CORD blood , *BACTERIAL diseases , *BLOOD sampling - Abstract
Quantification of fetal drug exposure remains challenging since sampling from the placenta or fetus during pregnancy is too invasive. Currently existing in vivo (e.g., cord blood sampling) and ex vivo (e.g., placenta perfusion) models have inherent limitations. A placenta-on-a-chip model is a promising alternative. A systematic search was performed in PubMed on 2 February 2023, and Embase on 14 March 2023. Studies were included where placenta-on-a-chip was used to investigate placental physiology, placenta in different obstetric conditions, and/or fetal exposure to maternally administered drugs. Seventeen articles were included that used comparable approaches but different microfluidic devices and/or different cultured maternal and fetal cell lines. Of these studies, four quantified glucose transfer, four studies evaluated drug transport, three studies investigated nanoparticles, one study analyzed bacterial infection and five studies investigated preeclampsia. It was demonstrated that placenta-on-a-chip has the capacity to recapitulate the key characteristics of the human placental barrier. We aimed to identify knowledge gaps and provide the first steps towards an overview of current protocols for developing a placenta-on-a-chip, that facilitates comparison of results from different studies. Although models differ, they offer a promising approach for in vitro human placental and fetal drug studies under healthy and pathological conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Comparative Pharmacokinetics of the Carbapenems.
- Author
-
Mouton, Johan W., Touw, Daan J., Horrevorts, Alphonsus M., and Vinks, Alexander A.T.M.M.
- Subjects
- *
ANTIBACTERIAL agents , *PHARMACOKINETICS - Abstract
During the last few decades, several carbapenems have been developed. The major characteristic of the newer drags, such as MK-826, is a prolonged half-life. Alternatively, some carbapenems have been developed that can be given orally, such as CS-834 and L-084. Although imipenem and panipenem have to be administered with a co-drug to prevent degradation by the enzyme dehydropeptidase-1 and reduce nephrotoxicity, the newer drugs such as meropenem, biapenem and lenapenem are relatively stable towards that enzyme. Structural modifications have, besides changes in pharmacology, also led to varying antimicrobial properties. For instance, meropenem is relatively more active against Gram-negative organisms than most other carbapenems, but is slightly less active against Gram-positive organisms. Except for half-life and bioavailability, the pharmacokinetic properties of the carbapenems are relatively similar. Distribution is mainly in extracellular bodywater, as observed both from the volumes of distribution and from blister studies. Some carbapenems have a better penetration in cerebrospinal fluid than others. In patients with renal dysfunction, doses have to be adjusted, and special care must be taken with imipenem/cilastatin and panipenem/betamipron to prevent accumulation of the co-drugs, as the pharmacokinetic properties of the co-drugs differ from those of the drugs themselves. However, toxicity of the co-drugs has not been shown. The carbapenems differ in proconvulsive activity. Imipenem shows relatively the highest proconvulsive activity, especially at higher concentrations. Pharmacodynamic studies have shown that the major surrogate parameter for antimicrobial efficacy is the percentage of time of the dosage interval above the minimum inhibitory concentration (MIC). The minimum percentage time above the MIC (TaM) needed for optimal effect is known in animals (30 to 50%), but not in humans. It is probably less than 100%, but may be higher than 50%. Dosage... [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
9. Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients".
- Author
-
Oude Munnink, Thijs H., Klein, Saskia K., and Touw, Daan J.
- Subjects
- *
KINASE inhibitors , *NILOTINIB , *CANCER patients , *INFORMED consent (Medical law) , *ITRACONAZOLE , *DRUG monitoring - Abstract
This document is a comment on a study that investigated the impact of CYP3A4*22 genotype-guided dosing of kinase inhibitors in cancer patients. The study found that upfront dose reductions based on CYP3A4*22 genotype did not result in similar exposure levels compared to wildtype patients on standard doses. The authors concluded that upfront dose reductions of all CYP3A4 metabolized kinase inhibitors should not be recommended. However, the comment suggests that for kinase inhibitors that are more sensitive to CYP3A4, dose reductions may still be necessary for CYP3A4*22 carriers to avoid overexposure. The comment provides a case example of a patient treated with dasatinib, a CYP3A4 sensitive substrate, and highlights the importance of therapeutic drug monitoring in these situations. Overall, the comment suggests that the impact of CYP3A4*22 polymorphisms on kinase inhibitor exposure may vary depending on the specific inhibitor and calls for caution in generalizing the study findings to all CYP3A4 metabolized kinase inhibitors. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
10. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study.
- Author
-
van der Kleij, Maud B. A., Guchelaar, Niels A. D., Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L., Bleckman, Roos F., Groenland, Stefanie L., van Eerden, Ruben A. G., Imholz, Alex L. T., Vulink, Annelie J. E., Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J. E., Desar, Ingrid M. E., Moes, Dirk-Jan A. R., Touw, Daan J., Koolen, Stijn L. W., Gelderblom, Hans, Reyners, An K. L., and van Erp, Nielka P.
- Abstract
Background: Therapeutic drug monitoring (TDM) – performing dose adjustments based on measured drug levels and established pharmacokinetic (PK) targets – could optimise treatment with drugs that show large interpatient variability in exposure. We evaluated the feasibility of TDM for multiple oral targeted therapies. Here we report on drugs for which routine TDM is not feasible. Methods: We evaluated drug cohorts from the Dutch Pharmacology Oncology Group – TDM study. Based on PK levels taken at pre-specified time points, PK-guided interventions were performed. Feasibility of TDM was evaluated, and based on the success and practicability of TDM, cohorts could be closed. Results: For 10 out of 24 cohorts TDM was not feasible and inclusion was closed. A high incidence of adverse events resulted in closing the cabozantinib, dabrafenib/trametinib, everolimus, regorafenib and vismodegib cohort. The enzalutamide and erlotinib cohorts were closed because almost all PK levels were above target. Other, non-pharmacological reasons led to closing the palbociclib, olaparib and tamoxifen cohort. Conclusions: Although TDM could help personalising treatment for many drugs, the above-mentioned reasons can influence its feasibility, usefulness and clinical applicability. Therefore, routine TDM is not advised for cabozantinib, dabrafenib/trametinib, enzalutamide, erlotinib, everolimus, regorafenib and vismodegib. Nonetheless, TDM remains valuable for individual clinical decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial.
- Author
-
Veldhuisen, Dirk J., Rienstra, Michiel, Mosterd, Arend, Alings, A. Marco, Asselt, Antoinette D.J., Bouvy, Marcel L, Tijssen, Jan G.P., Schaap, Jeroen, Wall, Ernst E., Voors, Adriaan A., Boorsma, Eva M., Lok, Dirk J.A., Crijns, Harry J.G.M., Schut, Astrid, Vijver, Marlene A.T., Voordes, Geert H.D., Vos, Agaath H., Maas‐Soer, Ester L., Smit, Nicoline W., and Touw, Daan J.
- Subjects
- *
VENTRICULAR ejection fraction , *DIGOXIN , *HEART failure patients , *ATRIAL fibrillation , *HEART failure - Abstract
Aims Methods Conclusions Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low‐dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment.The DECISION trial is a randomized, double‐blind, parallel‐group, placebo‐controlled event‐driven outcome trial which will investigate the efficacy and safety of low‐dose digoxin in patients with chronic HF and LVEF <50%. Both patients with sinus rhythm and atrial fibrillation will be enrolled and will be randomized (1:1) to low‐dose digoxin or matching placebo. To maintain a target serum digoxin concentration of 0.5–0.9 ng/ml, dose adjustments are made throughout follow‐up based on serum digoxin measurements with dummy values for the placebo group. The primary endpoint is a composite of CV mortality and total HF hospitalizations or total urgent hospital visits for worsening HF, and all endpoints are adjudicated blindly by a Clinical Event Committee. The estimated sample size was 982 patients who will be followed for a median of 3 years, and in December 2023 enrolment was completed after 1002 patients.The DECISION trial will provide important evidence regarding the effect of (low‐dose) digoxin on CV mortality and total HF hospitalizations and urgent hospital visits when added to contemporary HF treatment of patients with reduced or mildly reduced LVEF.Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03783429. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
- Author
-
Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B. A., Westerdijk, Kim, Guchelaar, Niels A. D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L. T, Otten, Hans-Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T. A., Gelderblom, Hans, Moes, Dirk Jan A. R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L. W., Mathijssen, Ron H. J., and Huitema, Alwin D. R.
- Subjects
- *
DRUG monitoring , *RENAL cell carcinoma , *SARCOMA , *SURVIVAL rate , *OVERALL survival - Abstract
Introduction and Objective: Pazopanib is registered for metastatic renal cell carcinoma and soft-tissue sarcoma (STS). Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic drug monitoring (TDM). Prior studies have defined target levels of drug exposure (≥ 20.5 mg/L) linked to prolonged progression-free survival (PFS), but the added value of using TDM remains unclear. This study investigates the effect of TDM of pazopanib in patients with STS on survival outcomes and dose-limiting toxicities (DLTs) and evaluates the feasibility of TDM-guided dosing. Methods: A TDM-guided cohort was compared to a non-TDM-guided cohort for PFS, overall survival (OS) and DLTs. PK samples were available from all patients, though not acted upon in the non-TDM-guided cohort. We evaluated the feasibility of TDM by comparing the proportion of underdosed patients in our TDM cohort with data from previous publications. Results: A total of 122 STS patients were included in the TDM-guided cohort (n = 95) and non-TDM-guided cohort (n = 27). The average exposure in the overall population was 30.5 mg/L and was similar in both groups. Median PFS and OS did not differ between the TDM-guided cohort and non-TDM-guided cohort (respectively 5.5 vs 4.4 months, p = 0.3, and 12.6 vs 10.1 months, p = 0.8). Slightly more patients in the non-TDM-guided cohort experienced DLTs (54%) compared to the TDM-guided cohort (44%). The proportion of underdosed patients (13.3%) was halved compared to historical data (26.7%). Conclusion: TDM reduced the proportion of patients with subtherapeutic exposure levels by ~ 50%. Nonetheless, the added value of TDM for achieving target trough levels of ≥ 20.5 mg/L for pazopanib on survival outcomes could not be confirmed in STS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Lessons learned from site-specific sampling and biological half-life of IGFII and IIE(68-88) peptide: a case study.
- Author
-
Muller Kobold, Anneke C., de Haan, Jacco J., Bokkers, Reinoud P.H., Ruiter, Simeon J.S., van den Heuvel, Marius C., Lentjes, Eef G.W.M., Touw, Daan J., and de Jong, Koert P.
- Subjects
- *
PEPTIDES , *HEPATIC veins , *RENAL veins , *INSULIN-like growth factor-binding proteins , *SOMATOMEDIN A - Abstract
This article presents a case study on non-islet cell tumor induced hypoglycemia (NICTH), a rare condition associated with mesenchymal tumors. The study focuses on a patient with metastatic solitary fibrous tumors (SFT) and severe hypoglycemic symptoms. The researchers measured levels of insulin-like growth factor (IGF)-II and IIE(68-88) peptide in various sampling sites, including the hepatic vein draining the largest SFT metastasis. They also measured these substances in peripheral venous blood samples taken at different timepoints after tumor resection to determine their half-life and correlate the levels with tumor size and clinical parameters. The findings provide insight into the contribution of liver metastases to hormone production and highlight the importance of site-specific sampling in understanding the metabolism of tumor cells. However, the study suggests that site-specific sampling may have limited value in identifying the dominant hormone-producing site in patients with SFT. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
14. Unexpected Amanita phalloides -Induced Hematotoxicity—Results from a Retrospective Study.
- Author
-
Visser, Miranda, Hof, Willemien F. J., Broek, Astrid M., van Hoek, Amanda, de Jong, Joyce J., Touw, Daan J., and Dekkers, Bart G. J.
- Subjects
- *
INTERNATIONAL normalized ratio , *NEPHROTOXICOLOGY , *POISONS , *ACADEMIC medical centers , *HEPATOTOXICOLOGY , *HEMODILUTION - Abstract
Introduction: Amanita phalloides poisoning is a serious health problem with a mortality rate of 10–40%. Poisonings are characterized by severe liver and kidney toxicity. The effect of Amanita phalloides poisonings on hematological parameters has not been systematically evaluated thus far. Methods: Patients with suspected Amanita phalloides poisonings were retrospectively selected from the hospital database of the University Medical Center Groningen (UMCG). Medical data—including demographics; liver, kidney, and blood parameters; treatment; and outcomes—were collected. The severity of the poisoning was scored using the poison severity score. Results: Twenty-eight patients were identified who were admitted to the UMCG with suspected Amanita phalloides poisoning between 1994 and 2022. A time-dependent decrease was observed for hemoglobin and hematocrit concentrations, leukocytes, and platelets. Six out of twenty-eight patients developed acute liver failure (ALF). Patients with ALF showed a higher increase in liver enzymes, international normalized ratios, and PSS compared to patients without ALF. Conversely, hemoglobin and platelet numbers were decreased even further in these patients. Three out of six patients with ALF died and one patient received a liver transplant. Conclusion: Our study shows that Amanita phalloides poisonings may be associated with hematotoxicity in patients. The quantification of hematological parameters is of relevance in intoxicated patients, especially in those with ALF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Effects of interrupting the enterohepatic circulation in amatoxin intoxications.
- Author
-
Varekamp, Jurriaan, Tan, Jia Lin, Stam, Janine, van den Berg, Aad P., van Rheenen, Patrick F., Touw, Daan J., and Dekkers, Bart G. J.
- Abstract
Interruption of the enterohepatic circulation is regarded as an effective way to treat patients with amatoxin poisoning. Nonetheless, its effectiveness has not yet been systematically evaluated. Therefore, we performed a systematic review to investigate the role of enterohepatic circulation on patient outcome and clinical laboratory values. We specifically sought to evaluate the effect of activated charcoal, which absorbs drugs and toxins in the gastrointestinal tract. A previously established database with data extracted from case reports and series from literature, supplemented with recent publications, was used. Patient characteristics, outcome, and laboratory values were evaluated. We included 133 publications describing a total of 1,119 unique cases. Survival was 75 per cent in the control group (n = 452), whereas in the group treated with single or multiple doses of activated charcoal (n = 667) survival was 83 per cent (P < 0.001, odds ratio 1.89 [95 per cent confidence interval 1.40–2.56]). Furthermore, no difference in peak values of alanine aminotransferase and aspartate aminotransferase activities were observed, whereas peak values of total serum bilirubin concentration and international normalized ratio were statistically significantly reduced in patients treated with activated charcoal. The ability of activated charcoal to enhance the elimination of amatoxin through interruption of the enterohepatic circulation offers a potentially safe and inexpensive therapy for patients in the post-absorptive phase. Limitations include the potential for publication bias, the lack of universal confirmation of amatoxin concentrations, and the inability to directly measure enterohepatic circulation of amatoxin. Treatment with activated charcoal in patients with amatoxin poisoning was associated with a greater chance of a successful outcome. Additionally, activated charcoal was associated with a reduction in markers of liver function, but not markers of liver injury. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Unraveling Hematotoxicity of α-Amanitin in Cultured Hematopoietic Cells.
- Author
-
Hof, Willemien F. J., Visser, Miranda, de Jong, Joyce J., Rajasekar, Marian N., Schuringa, Jan Jacob, de Graaf, Inge A. M., Touw, Daan J., and Dekkers, Bart G. J.
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cells , *TRYPAN blue , *CD34 antigen , *CELL survival , *APOPTOSIS - Abstract
Amanita phalloides poisonings account for the majority of fatal mushroom poisonings. Recently, we identified hematotoxicity as a relevant aspect of Amanita poisonings. In this study, we investigated the effects of the main toxins of Amanita phalloides, α- and β-amanitin, on hematopoietic cell viability in vitro. Hematopoietic cell lines were exposed to α-amanitin or β-amanitin for up to 72 h with or without the pan-caspase inhibitor Z-VAD(OH)-FMK, antidotes N-acetylcysteine, silibinin, and benzylpenicillin, and organic anion-transporting polypeptide 1B3 (OATP1B3) inhibitors rifampicin and cyclosporin. Cell viability was established by trypan blue exclusion, annexin V staining, and a MTS assay. Caspase-3/7 activity was determined with Caspase-Glo assay, and cleaved caspase-3 was quantified by Western analysis. Cell number and colony-forming units were quantified after exposure to α-amanitin in primary CD34+ hematopoietic stem cells. In all cell lines, α-amanitin concentration-dependently decreased viability and mitochondrial activity. β-Amanitin was less toxic, but still significantly reduced viability. α-Amanitin increased caspase-3/7 activity by 2.8-fold and cleaved caspase-3 by 2.3-fold. Z-VAD(OH)-FMK significantly reduced α-amanitin-induced toxicity. In CD34+ stem cells, α-amanitin decreased the number of colonies and cells. The antidotes and OATP1B3 inhibitors did not reverse α-amanitin-induced toxicity. In conclusion, α-amanitin induces apoptosis in hematopoietic cells via a caspase-dependent mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. GC–MS analysis of 4-hydroxyproline: elevated proline hydroxylation in metformin-associated lactic acidosis and metformin-treated Becker muscular dystrophy patients.
- Author
-
Baskal, Svetlana, Posma, Rene A., Bollenbach, Alexander, Dieperink, Willem, Bakker, Stephan J. L., Nijsten, Maarten W., Touw, Daan J., and Tsikas, Dimitrios
- Abstract
Metformin (N,N-dimethylbiguanide), an inhibitor of gluconeogenesis and insulin sensitizer, is widely used for the treatment of type 2 diabetes. In some patients with renal insufficiency, metformin can accumulate and cause lactic acidosis, known as metformin-associated lactic acidosis (MALA, defined as lactate ≥ 5 mM, pH < 7.35, and metformin concentration > 38.7 µM). Here, we report on the post-translational modification (PTM) of proline (Pro) to 4-hydroxyproline (OH-Pro) in metformin-associated lactic acidosis and in metformin-treated patients with Becker muscular dystrophy (BMD). Pro and OH-Pro were measured simultaneously by gas chromatography–mass spectrometry before, during, and after renal replacement therapy in a patient admitted to the intensive care unit (ICU) because of MALA. At admission to the ICU, plasma metformin concentration was 175 µM, with a corresponding lactate concentration of 20 mM and a blood pH of 7.1. Throughout ICU admission, the Pro concentration was lower compared to healthy controls. Renal excretion of OH-Pro was initially high and decreased over time. Moreover, during the first 12 h of ICU admission, OH-Pro seems to be renally secreted while thereafter, it was reabsorbed. Our results suggest that MALA is associated with hyper-hydroxyprolinuria due to elevated PTM of Pro to OH-Pro by prolyl-hydroxylase and/or inhibition of OH-Pro metabolism in the kidneys. In BMD patients, metformin, at the therapeutic dose of 3 × 500 mg per day for 6 weeks, increased the urinary excretion of OH-Pro suggesting elevation of Pro hydroxylation to OH-Pro. Our study suggests that metformin induces specifically the expression/activity of prolyl-hydroxylase in metformin intoxication and BMD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients.
- Author
-
Koomen, Jeroen V., Knobbe, Tim J., Zijp, Tanja R., Kremer, Daan, Gan, C. Tji, Verschuuren, Erik A. M., Bakker, Stephan J. L., Touw, Daan J., and Colin, Pieter J.
- Subjects
- *
LUNG transplantation , *BLOOD plasma , *KIDNEY transplantation , *LUNGS , *DRUG monitoring , *TACROLIMUS - Abstract
Background and Objective: Historically, dosing of tacrolimus is guided by therapeutic drug monitoring (TDM) of the whole blood concentration, which is strongly influenced by haematocrit. The therapeutic and adverse effects are however expected to be driven by the unbound exposure, which could be better represented by measuring plasma concentrations. Objective: We aimed to establish plasma concentration ranges reflecting whole blood concentrations within currently used target ranges. Methods: Plasma and whole blood tacrolimus concentrations were determined in samples of transplant recipients included in the TransplantLines Biobank and Cohort Study. Targeted whole blood trough concentrations are 4–6 ng/mL and 7–10 ng/mL for kidney and lung transplant recipients, respectively. A population pharmacokinetic model was developed using non-linear mixed-effects modelling. Simulations were performed to infer plasma concentration ranges corresponding to whole blood target ranges. Results: Plasma (n = 1973) and whole blood (n = 1961) tacrolimus concentrations were determined in 1060 transplant recipients. A one-compartment model with fixed first-order absorption and estimated first-order elimination characterised observed plasma concentrations. Plasma was linked to whole blood using a saturable binding equation (maximum binding 35.7 ng/mL, 95% confidence interval (CI) 31.0–40.4 ng/mL; dissociation constant 0.24 ng/mL, 95% CI 0.19–0.29 ng/mL). Model simulations indicate that patients within the whole blood target range are expected to have plasma concentrations (95% prediction interval) of 0.06–0.26 ng/mL and 0.10–0.93 ng/mL for kidney and lung transplant recipients, respectively. Conclusion: Whole blood tacrolimus target ranges, currently used to guide TDM, were translated to plasma concentration ranges of 0.06–0.26 ng/mL and 0.10–0.93 ng/mL for kidney and lung transplant recipients, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Twenty-four hour urinary cortisol excretion and the metabolic syndrome in prednisolone-treated renal transplant recipients.
- Author
-
de Vries, Laura V., de Jong, Wilhelmina H.A., Touw, Daan J., Berger, Stefan P., Navis, Gerjan, Kema, Ido P., and Bakker, Stephan J.L.
- Subjects
- *
PREDNISOLONE , *KIDNEY transplantation , *METABOLIC disorders , *METABOLIC syndrome , *HYDROCORTISONE - Abstract
Chronic prednisolone treatment in renal transplant recipients (RTR) causes metabolic abnormalities, which cluster in the metabolic syndrome (MS). It also suppresses the hypothalamic–pituitaryadrenal (HPA)-axis. We investigated whether HPA-axis suppression, as measured by 24 h urinary cortisol excretion, is associated with presence of the MS and its individual components, in outpatient RTR with a functioning graft for >1 year. Urinary cortisol was measured in 24 h urine, using LC–MS/MS (LOQ 0.30 nmol/L). We included 563 RTR (age 51 ± 12 years; 54% male) at median 6.0 [IQR, 2.6–11.5] years post-transplantation. MS was present in 439/563 RTR (78%). Median 24 h urinary cortisol excretion was 2.0 [IQR, 0.9–5.1] nmol/24 h. Twenty-four hour urinary cortisol excretion was independently associated with MS presence (OR = 0.80 [95% CI, 0.66–0.98], P = 0.02). It was also independently associated with bodyweight (st.β = −0.11, P = 0.007), waist circumference (st.β = −0.10, P = 0.01), BMI (st.β = −0.14, P = 0.001), fasting triglycerides (st.β = −0.15, P = 0.001), diabetes (st.β = −0.12, P = 0.005), and number of antihypertensives used (st.β = −0.13, P = 0.003). Suppressed HPA-axis activity, as reflected by decreased 24 h urinary cortisol excretion, is associated with higher prevalence of MS and its individual components (i.e. central obesity, dyslipidemia, diabetes, hypertension) in prednisolone-treated RTR. Assessment of 24 h urinary cortisol excretion by LC–MS/MS may be a tool to monitor metabolic side-effects of prednisolone in RTR. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Endobronchial Valve Treatment Does Not Cause Significant Nickel Deposition in Lung Tissue.
- Author
-
Roodenburg, Sharyn A., Pouwels, Simon D., Klooster, Karin, Touw, Daan J., and Slebos, Dirk-Jan
- Subjects
- *
LUNG physiology , *PROSTHETICS , *NICKEL , *HEMOPTYSIS , *ARTIFICIAL implants , *TREATMENT effectiveness , *OBSTRUCTIVE lung diseases , *FORCED expiratory volume , *GRANULATION tissue , *ATELECTASIS , *VIDEO-assisted thoracic surgery , *BRONCHOSCOPY , *PULMONARY emphysema , *PNEUMONECTOMY - Abstract
Bronchoscopic lung volume reduction using endobronchial valves (EBVs) is a treatment option for patients with severe emphysema. These EBVs are made out of a nitinol mesh covered by a silicone layer. Nitinol is an alloy of nickel and titanium and is commonly used in implantable medical devices because of its biocompatibility and memory-shape properties. However, there are some concerns that nickel ions can be released from nitinol-containing devices which might cause adverse health effects, especially in patients with a known nickel hypersensitivity. In vitro, it was found that EBV release significant amounts of nickel in the first hours. Our aim was to assess the nickel concentration in lung tissue from a patient who previously underwent EBV treatment but, due to treatment failure, underwent lung volume reduction surgery and to compare this to a reference sample. We found no significant difference in the median nickel concentration between the EBV-treated patient and the non-EBV-treated patient (0.270 vs. 0.328 μg/g, respectively, p = 0.693) and these concentrations were also comparable to previously published nickel concentrations in human lung tissue samples not having any medically implanted devices in the lung. Our results suggest that there is no significant long-term nickel deposition in lung tissue after EBV treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Tremor, Daily Functioning, and Health-Related Quality of Life in Solid Organ Transplant Recipients.
- Author
-
Riemersma, Niels L., Kremer, Daan, Knobbe, Tim J., Tji Gan, C., Nolte, Svea, Gomes-Neto, António W., Blokzijl, Hans, de Meijer, Vincent E., Damman, Kevin, Eisenga, Michele F., Drost, Gea, Elting, Jan Willem J., Touw, Daan J., Berger, Stefan P., Bakker, Stephan J. L., and Madelein van der Stouwe, A. M.
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *QUALITY of life , *TREMOR , *LOGISTIC regression analysis - Abstract
Solid organ transplant recipients (SOTR) frequently report tremor. Data concerning tremorrelated impairment and its potential impact on health-related quality of life (HRQoL) are lacking. This cross-sectional study assesses impact of tremor on activities of daily living and HRQoL using validated questionnaires among SOTR enrolled in the TransplantLines Biobank and Cohort Study. We included 689 SOTR (38.5% female, mean [±SD] age 58 [±14] years) at median [interquartile range] 3 [1–9] years after transplantation, of which 287 (41.7%) reported mild or severe tremor. In multinomial logistic regression analyses, whole blood tacrolimus trough concentration was an independent determinant of mild tremor (OR per µg/L increase: 1.11, 95% CI: 1.02 to 1.21, p = 0.019). Furthermore, in linear regression analyses, severe tremor was strongly and independently associated with lower physical and mental HRQoL (β = −16.10, 95% CI: −22.23 to −9.98, p < 0.001 and β = −12.68, 95% CI: −18.23 to −7.14, p < 0.001 resp.). SOTR frequently report tremor-related impairment of activities of daily living. Tacrolimus trough concentrations appeared as a main determinant of tremor among SOTR. The strong and independent association of tremor-related impairment with lower HRQoL warrants further studies into the effects of tacrolimus on tremor [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Iron Deficiency and Nephrotoxic Heavy Metals: A Dangerous Interplay?
- Author
-
Rawee, Pien, Kremer, Daan, Nolte, Ilja M., Leuvenink, Henri G. D., Touw, Daan J., De Borst, Martin H., Bakker, Stephan J. L., Hanudel, Mark R., and Eisenga, Michele F.
- Subjects
- *
HEAVY metals , *IRON , *IRON deficiency , *IRON supplements , *DISEASE risk factors , *LITERATURE reviews - Abstract
Heavy metals are common in our environment, and all individuals are exposed to them to some extent. These toxic metals have several harmful effects on the body, including the kidney, which is a very sensitive organ. Indeed, heavy metal exposure has been linked to an increased risk of chronic kidney disease (CKD) and its progression, which may be explained by the well-established nephrotoxic effects of these metals. In this hypothesis and narrative literature review, we will shed light on the potential role that another highly common problem in patients with CKD, iron deficiency, may play in the damaging effects of heavy metal exposure in this patient group. Iron deficiency has previously been linked with an increased uptake of heavy metals in the intestine due to the upregulation of iron receptors that also take up other metals. Furthermore, recent research suggests a role of iron deficiency in the retention of heavy metals in the kidney. Therefore, we hypothesize that iron deficiency plays a crucial role in the damaging effects of heavy metal exposure in patients with CKD and that iron supplementation might be a strategy to combat these detrimental processes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review.
- Author
-
Maring, Jan Gerard, Eijsink, Job F. H., Tichelaar, Friso D., Veluwenkamp-Worawutputtapong, Pawida, Postma, Maarten J., Touw, Daan J., and de Groot, Jan Willem B.
- Subjects
- *
ONLINE information services , *MEDICAL information storage & retrieval systems , *SYSTEMATIC reviews , *HEALTH outcome assessment , *METASTASIS , *COLORECTAL cancer , *QUALITY of life , *DESCRIPTIVE statistics , *LITERATURE reviews , *MEDLINE , *EVALUATION - Abstract
Simple Summary: Patient-Reported Outcome Measures (PROMs) provide reports from patients on their own health, quality of life, or functional status associated with their disease, and the care they have received. In treating metastatic colorectal cancer (CRC), it is important to obtain information about the impact of a treatment on various aspects of patients' lives besides overall survival. We performed a review on the use of PROMs in phase III clinical trials started between 2010 and 2021, evaluating systemic therapy in patients with metastatic CRC. We demonstrate that the quality of reporting on PROMs has increased over the last decade, but is still not optimal. Moreover, PROM results are underreported in studies on metastatic CRC, impeding the optimal incorporation of trial and PROM results into daily clinical practice. Purpose: To perform a scoping review on the use of Patient-Reported Outcome Measures (PROMs) in randomized trials on systemic therapy in patients with metastatic colorectal cancer (mCRC) between 2010 and 2021. Methods: First, a search on clinicaltrials.gov was performed, looking for randomized trials in mCRC. The use of PROMs was analyzed quantitatively. Subsequently, we assessed the completeness of PROM reporting based on the CONSORT PRO extension in publications related to the selected trials acquired using Embase and PubMed. Results: A total of 46/176 trials were registered on clinicaltrials.gov used PROMs. All these trials used validated PROM instruments. The EORTC QLQ-C30 was most frequently used (37 times), followed by the EQ-5D (21 times) and the EORTC QLQ-CR29 (six times). A total of 56/176 registered trials were published. In 35% (n = 20), the results of the PROMs were available. Overall, 7/20 (35%) trials documented all items of the CONSORT PRO extension and quality of reporting according to the CONSORT PRO extension was higher than in the period 2004–2012. In 3/20 (15%) of the published trials, the results of PROMs were not discussed nor included in the positioning of the new treatment compared to the reference treatment. Conclusion: When PROMs are used, the quality of reporting on patient-reported outcomes is improving, but this must continue in order to optimize the translation of trial results to individual patient values. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease.
- Author
-
Weening, Eerde H., Al-Mubarak, Ali A., Dokter, Martin M., Dickstein, Kenneth, Lang, Chim C., Ng, Leong L., Metra, Marco, van Veldhuisen, Dirk J., Touw, Daan J., de Boer, Rudolf A., Gansevoort, Ron T., Voors, Adriaan A., Bakker, Stephan J. L., van der Meer, Peter, and Bomer, Nils
- Subjects
- *
SEXUAL dimorphism , *HEART failure , *METABOLIC syndrome , *SELENIUM , *DISEASE prevalence , *HEART diseases - Abstract
Background: Serum selenium levels have been associated with the incidence of heart failure (HF) and signs of the metabolic syndrome. In addition, notable differences have been reported between males and females in food intake and micronutrient metabolism, possibly explaining different health outcomes. Objective: Our objective was to elucidate sex-specific, cross-sectional phenotypic differences in the association of serum selenium concentrations with parameters of metabolic syndrome and HF. Methods: We investigated data from individuals from a community-based cohort (PREVEND; N = 4288) and heart failure cohort (BIOSTAT-CHF; N = 1994). In both populations, cross-sectional analyses were performed for potential interaction (p < 0.1) between sex and serum selenium with overlapping signs and clinical parameters of the metabolic syndrome and HF. Results: Baseline selenium levels of the total cohort were similar between PREVEND (85.7 μg/L) and BIOSTAT-CHF (89.1 μg/L). Females with lower selenium levels had a higher BMI and increased prevalence of diabetes than females with higher selenium, in both PREVEND (pinteraction < 0.001; pinteraction = 0.040, resp.) and BIOSTAT-CHF (pinteraction = 0.021; pinteraction = 0.024, resp.), while opposite associations were observed for males. Additionally, in females, but not in males, lower selenium was associated with a higher prevalence of myocardial infarction (MI) in PREVEND (pinteraction = 0.021) and BIOSTAT-CHF (pinteraction = 0.084). Conclusion: Lower selenium was associated with a higher BMI and increased prevalence of diabetes in females, opposite to males, and was also associated with more MI in females. Interventional studies are needed to validate this observation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study.
- Author
-
Grit, Geeske F., Märtson, Anne-Grete, Knoester, Marjolein, Toren-Wielema, Marlous L., and Touw, Daan J.
- Subjects
- *
VARICELLA-zoster virus , *VIRUS diseases , *ACYCLOVIR , *IMMUNOCOMPROMISED patients , *DRUG monitoring - Abstract
Background: Acyclovir and valacyclovir are used for the treatment and prophylaxis of infections with herpes simplex virus (HSV) and varicella zoster virus (VZV). The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir. Methods: Patients were retrospectively selected, based on therapeutic drug monitoring for acyclovir, to create a population pharmacokinetic (PK) model in Pmetrics. This PK model was used to develop a PK/PD model to study the effect of acyclovir levels on VZV viral load in plasma in immunocompromised patients. Results: Immunocompromised patients with known VZV viral loads in plasma were included for PK/PD modelling (N = 4, with 23 measure points); they were part of the population of 43 patients used for PK model building. The PK/PD model described the data well (r2 = 0.83). This is a hopeful first step in clarifying the pharmacodynamics of acyclovir; however, the data in this study are limited. Conclusions: Our preliminary PK/PD model can be used in further research to determine the effect of acyclovir levels on VZV viral load. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Amanitin intoxication: effects of therapies on clinical outcomes – a review of 40 years of reported cases.
- Author
-
Tan, Jia Lin, Stam, Janine, van den Berg, Aad P., van Rheenen, Patrick F., Dekkers, Bart G. J., and Touw, Daan J.
- Subjects
- *
TREATMENT effectiveness , *INTERNATIONAL normalized ratio , *SURVIVAL rate , *ALANINE aminotransferase , *ASPARTATE aminotransferase - Abstract
Amanita phalloides poisoning causes severe liver damage which may be potentially fatal. Several treatments are available, but their effectiveness has not been systematically evaluated. We performed a systematic review to investigate the effect of the most commonly used therapies: N-acetylcysteine (NAC), benzylpenicillin (PEN), and silibinin (SIL) on patient outcomes. In addition, other factors contributing to patient outcomes are identified. We searched MEDLINE and Embase for case series and case reports that described patient outcomes after poisoning with amanitin-containing Amanita mushrooms. We extracted clinical characteristics, treatment details, and outcomes. We used the liver item from the Poisoning Severity Score (PSS) to categorize intoxication severity. We included 131 publications describing a total of 877 unique cases. The overall survival rate of all patients was 84%. Patients receiving only supportive care had a survival rate of 59%. The use of SIL or PEN was associated with a 90% (OR 6.40 [3.14–13.04]) and 89% (OR 5.24 [2.87–9.56]) survival rate, respectively. NAC/SIL combination therapy was associated with 85% survival rate (OR 3.85 [2.04, 7.25]). NAC/PEN/SIL treatment group had a survival rate of 76% (OR 2.11 [1.25, 3.57]). Due to the limited number of cases, the use of NAC alone could not be evaluated. Additional analyses in 'proven cases' (amanitin detected), 'probable cases' (mushroom identified by mycologist), and 'possible cases' (neither amanitin detected nor mushroom identified) showed comparable results, but the results did not reach statistical significance. Transplantation-free survivors had significantly lower peak values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total serum bilirubin (TSB), and international normalized ratio (INR) compared to liver transplantation survivors and patients with fatal outcomes. Higher peak PSS was associated with increased mortality. Based on data available, no statistical differences could be observed for the effects of NAC, PEN or SIL in proven poisonings with amanitin-containing mushrooms. However, monotherapy with SIL or PEN and combination therapy with NAC/SIL appear to be associated with higher survival rates compared to supportive care alone. AST, ALT, TSB, and INR values are possible predictors of potentially fatal outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Electronic Smart Blister Packages to Monitor and Support Medication Adherence: A Usability Study.
- Author
-
Izzah, Zamrotul, Zijp, Tanja R, Åberg, Christoffer, Touw, Daan J, and van Boven, Job FM
- Subjects
- *
PATIENT compliance , *MEDICAL personnel , *OLDER people , *CLINICAL trials - Abstract
Purpose: An electronic version of the Dosepak® (EDP) which records date and time of dosing events has been developed to monitor adherence to medication packaged in blisters. This study aimed to evaluate its usability and acceptance and to monitor dose-taking adherence for optimal implementation in future clinical trials and practice. Methods: Healthy volunteers aged over 18 years were asked to dispense placebo tablets twice daily from EDPs equipped with a re-usable electronic module for a total duration of four weeks. Afterwards, subjects were asked to complete an online questionnaire and partake in a short one-on-one interview. The usability of the EDP was assessed using the System Usability Scale (SUS), while dose-taking adherence was monitored by EDP records, pill counting, and self-report. The short interview explored user experiences in more detail. Results: Twenty subjects with median [IQR] age 41.5 [32– 49.8] years, 55% female, 45% healthcare professionals, and 20% chronic medication users completed the study and found the EDP easy to use, with a mean [SD] SUS score of 78.0 [11.2]. Median [IQR] dose-taking adherence was 89% [82– 95%] based on EDP records, 96.5% [89– 100%] based on pill counting, 92% [91– 96%] based on self-report, and the levels differed significantly (p < 0.05). Four themes emerged from the interviews: user preference, experience, patient burden, and ideas for improvement. Most participants preferred smaller sized blisters. They found the EDP simple to use and did not see any patient burden for its use in trials or clinical practice. Some reported forgetfulness and suggested reminders built into the blister or sent to their mobile phones. Adequate information or instruction should also be provided for older people and polypharmacy patients. Conclusion: EDP had good perceived usability, was well accepted, and differed significantly from other adherence measurement methods. This study provides input to further guide scale-up of the blister packages. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review.
- Author
-
Wiersma, Thomas K., Visschedijk, Marijn C., de Boer, Nanne K., Lub-de Hooge, Marjolijn N., Prins, Jelmer R., Touw, Daan J., and Mian, Paola
- Subjects
- *
INFLAMMATORY bowel diseases , *ADALIMUMAB , *PREGNANCY , *PHARMACOKINETICS , *DRUG therapy , *PREGNANT women - Abstract
Due to ethical and practical reasons, a knowledge gap exists on the pharmacokinetics (PK) of inflammatory bowel disease (IBD)-related drugs in pregnant women with IBD. Before evidence-based dosing can be proposed, insight into the PK has to be gained to optimize drug therapy for both mother and fetus. This systematic review aimed to describe the effect of pregnancy and IBD on the PK of drugs used for IBD. One aminosalicylate study, two thiopurine studies and twelve studies with biologicals were included. Most drugs within these groups presented data over multiple moments before, during and after pregnancy, except for mesalazine, ustekinumab and golimumab. The studies for mesalazine, ustekinumab and golimumab did not provide enough data to demonstrate an effect of pregnancy on concentration and PK parameters. Therefore, no evidence-based dosing advice was given. The 6-thioguanine nucleotide levels decreased during pregnancy to 61% compared to pre-pregnancy levels. The potentially toxic metabolite 6-methylmercaptopurine (6-MMP) increased to maximal 209% of the pre-pregnancy levels. Although the PK of the thiopurines changed throughout pregnancy, no evidence-based dosing advice was provided. One study suggested that caution should be exercised when the thiopurine dose is adjusted, due to shunting 6-MMP levels. For the biologicals, infliximab levels increased, adalimumab stayed relatively stable and vedolizumab levels tended to decrease during pregnancy. Although the PK of the biologicals changed throughout pregnancy, no evidence-based dosing advice for biologicals was provided. Other drugs retrieved from the literature search were mesalazine, ustekinumab and golimumab. We conclude that limited studies have been performed on PK parameters during pregnancy for drugs used in IBD. Therefore, more extensive research to determine the values of PK parameters is warranted. After gathering the PK data, evidence-based dosing regimens can be developed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin.
- Author
-
Rozenveld, Eric, Punt, Nieko, van Faassen, Martijn, van Beek, André P., and Touw, Daan J.
- Subjects
- *
PROTEIN binding , *HYDROCORTISONE , *GLOBULINS , *PHARMACOKINETICS , *ADRENAL insufficiency - Abstract
Background: Patients with adrenal insufficiency are treated with oral hydrocortisone (HC) to compensate for the loss of endogenous cortisol production. Intrinsic imperfections of cortisol replacement strategies in mimicking normal cortisol secretion are the underlying cause of the increased morbidity and mortality of patients suffering from secondary adrenal insufficiency (SAI). To improve oral hydrocortisone substitution therapy, a better understanding of its pharmacokinetics (PK) is necessary. The previous PK model did not include protein binding. It is known that protein binding can impact hydrocortisone pharmacokinetics. The aim of this study is to describe HC pharmacokinetics including the protein-binding state using Edsim++ (Mediware, Prague) pharmacokinetic modeling software, paving the way for an in-silico tool suitable for drug delivery design. Methods: A total of 46 patients with SAI participated in a randomized double-blind crossover study Patients randomly received a low dose of HC (0.2–0.3 mg/kg body weight/day) for 10 weeks, followed by a high dose (0.4–0.6 mg/kg body weight/day) for another 10 weeks, or vice versa. Plasma samples were obtained and analyzed for free and total hydrocortisone. Single compartment population pharmacokinetic analysis was performed using an extended Werumeus-Buning model built in Edsim++. This model includes a mathematical approach for estimating free cortisol by Nguyen et al., taking the protein binding of HC to albumin and hydrocortisone-binding globulin (CBG, transcortin) into consideration, as well as different states of CBG which affect binding kinetics to HC. The goodness of fit for observed versus predicted values was calculated. Results and conclusions: Nguyen's formula for free cortisol estimation was successfully implemented in a pharmacokinetic model. The model shows high Spearman's correlation for observed versus predicted hydrocortisone concentrations. Significantly higher correlations (Spearman's r, 0.901 vs. 0.836) between total and free hydrocortisone AUC24 (area-under the curve over 24 h) are found when comparing new and old models. This new model was used to simulate the plasma concentration–time behavior of a more suitable hydrocortisone formulation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Pharmacometabolomics may be the next stamp in the pharmacogenetic passport.
- Author
-
Klont, Frank, Hof, Marieke A.J., Nijdam, Fleur B., Touw, Daan J., Bakker, Stephan J.L., Hopfgartner, Gérard, Kosterink, Jos G.W., and Hak, Eelko
- Subjects
- *
PASSPORTS , *INDIVIDUALIZED medicine , *DRUGS , *PHARMACOGENOMICS , *METABOLOMICS - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Plasma Thallium Concentration, Kidney Function, Nephrotoxicity and Graft Failure in Kidney Transplant Recipients.
- Author
-
Kremer, Daan, Riemersma, Niels L., Groothof, Dion, Sotomayor, Camilo G., Eisenga, Michele F., Post, Adrian, Knobbe, Tim J., Touw, Daan J., and Bakker, Stephan J. L.
- Subjects
- *
INDUCTIVELY coupled plasma mass spectrometry , *KIDNEY physiology , *KIDNEY transplantation , *THALLIUM , *KIDNEY failure - Abstract
The nephrotoxic effects of heavy metals have gained increasing scientific attention in the past years. Recent studies suggest that heavy metals, including cadmium, lead, and arsenic, are detrimental to kidney transplant recipients (KTR) even at circulating concentrations within the normal range, posing an increased risk for graft failure. Thallium is another highly toxic heavy metal, yet the potential consequences of the circulating thallium concentrations in KTR are unclear. We measured plasma thallium concentrations in 672 stable KTR enrolled in the prospective TransplantLines Food and Nutrition Biobank and Cohort Study using inductively coupled plasma mass spectrometry. In cross-sectional analyses, plasma thallium concentrations were positively associated with kidney function measures and hemoglobin. We observed no associations of thallium concentration with proteinuria or markers of tubular damage. In prospective analyses, we observed no association of plasma thallium with graft failure and mortality during a median follow-up of 5.4 [interquartile range: 4.8 to 6.1] years. In conclusion, in contrast with other heavy metals such as lead, cadmium, and arsenic, there is no evidence of tubular damage or thallium nephrotoxicity for the range of circulating thallium concentrations observed in this study. This is further evidenced by the absence of associations of plasma thallium with graft failure and mortality in KTR. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND.
- Author
-
Al‐Mubarak, Ali A., Grote Beverborg, Niels, Suthahar, Navin, Gansevoort, Ron T., Bakker, Stephan J.L., Touw, Daan J., de Boer, Rudolf A., van der Meer, Peter, and Bomer, Nils
- Subjects
- *
HEART failure , *SELENIUM , *BODY mass index , *IRON deficiency , *C-reactive protein - Abstract
Aim: To elucidate the relationship between serum selenium levels and the risk of mortality and new‐onset heart failure (HF) in the general adult population. Methods and results: Selenium was measured in a Dutch cohort and a retrospective analysis of prospectively assessed data was performed. Main outcome measures were all‐cause mortality and incidence of new‐onset HF separately, and combined as a composite endpoint. Serum selenium was measured in 5973 subjects and mean selenium concentration was 84.6 (±19.5) µg/L. Mean age was 53.6 (±12.1) years and 3103 subjects (52%) were female. Median follow‐up was 8.4 years. Selenium levels associated positively with female sex, higher total cholesterol and glucose concentrations, and associated negatively with incidence of anaemia, iron deficiency, current smoking, increased C‐reactive protein levels, and higher body mass index. Univariate analysis on all subjects showed no association of continuous selenium concentrations, per 10 µg/L increase, with the composite endpoint (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.87–1.06, p = 0.407). However, significant interaction with smoking status was observed. In non‐smoking subjects (n = 4288), continuous selenium concentrations were independently associated with reduced mortality risk (HR 0.87, 95% CI 0.79–0.96, p = 0.005), lower risk of new‐onset HF (HR 0.82, 95% CI 0.69–0.96, p = 0.017), as well as reduced risk of the composite endpoint (HR 0.86, 95% CI 0.79–0.94, p = 0.001). In smoking subjects, no associations were found. Conclusion: Serum selenium was independently associated with multiple indicators of the metabolic syndrome. In addition, high selenium levels were independently associated with reduced mortality and new‐onset HF in non‐smokers. Well‐powered interventional studies are necessary to evaluate the potential benefit of repleting selenium, especially in non‐smoking subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. High selenium levels associate with reduced risk of mortality and new-onset heart failure: data from PREVEND.
- Author
-
Al-Mubarak, Ali A., Beverborg, Niels Grote, Suthahar, Navin, Gansevoort, Ron T., Bakker, Stephan J. L., Touw, Daan J., de Boer, Rudolf A., van der Meer, Peter, and Bomer, Nils
- Subjects
- *
BLOOD sugar analysis , *HEART failure risk factors , *C-reactive protein , *STATISTICS , *CONFIDENCE intervals , *RETROSPECTIVE studies , *DISEASE incidence , *RISK assessment , *SEX distribution , *DESCRIPTIVE statistics , *IRON deficiency anemia , *SMOKING , *BODY mass index , *SELENIUM , *LONGITUDINAL method , *CHOLESTEROL , *PROPORTIONAL hazards models ,MORTALITY risk factors - Abstract
Aim To elucidate the relationship between serum selenium levels and the risk of mortality and new-onset heart failure (HF) in the general adult population. Methods and results Selenium was measured in a Dutch cohort and a retrospective analysis of prospectively assessed data was performed. Main outcome measures were all-cause mortality and incidence of new-onset HF separately, and combined as a composite endpoint. Serum selenium was measured in 5973 subjects and mean selenium concentration was 84.6 (±19.5) µg/L. Mean age was 53.6 (±12.1) years and 3103 subjects (52%) were female. Median follow-up was 8.4 years. Selenium levels associated positively with female sex, higher total cholesterol and glucose concentrations, and associated negatively with incidence of anaemia, iron deficiency, current smoking, increased C-reactive protein levels, and higher body mass index. Univariate analysis on all subjects showed no association of continuous selenium concentrations, per 10 µg/L increase, with the composite endpoint (hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.87-1.06, p = 0.407). However, significant interaction with smoking status was observed. In non-smoking subjects (n = 4288), continuous selenium concentrations were independently associated with reduced mortality risk (HR 0.87, 95% CI 0.79-0.96, p = 0.005), lower risk of new-onset HF (HR 0.82, 95% CI 0.69-0.96, p = 0.017), as well as reduced risk of the composite endpoint (HR 0.86, 95% CI 0.79-0.94, p = 0.001). In smoking subjects, no associations were found. Conclusion Serum selenium was independently associated with multiple indicators of the metabolic syndrome. In addition, high selenium levels were independently associated with reduced mortality and new-onset HF in non-smokers. Well-powered interventional studies are necessary to evaluate the potential benefit of repleting selenium, especially in non-smoking subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
- Author
-
Alghanem, Sarah, Paterson, Iona, Touw, Daan J., and Thomson, Alison H.
- Subjects
- *
AMINOGLYCOSIDES , *CYSTIC fibrosis treatment , *ANTIBIOTICS , *ANTIBACTERIAL agents , *PHARMACOKINETICS - Abstract
Objectives To investigate factors affecting aminoglycoside clearance in adult patients with cystic fibrosis who received multiple courses of antibiotic therapy over a period of up to 15 years. Methods Aminoglycoside concentration–time data and relevant clinical characteristics were collated from clinical pharmacokinetic databases established in Glasgow, Scotland and The Hague, The Netherlands. Data from Glasgow (1993–2009) were used for population model development; data from The Hague (2002–11) were used for model validation. NONMEM was used to determine structural and covariate models, with a particular focus on between-occasion variability and changes in aminoglycoside handling over multiple courses of therapy. Results The Glasgow dataset comprised 1075 courses of aminoglycoside therapy (96% tobramycin and 4% gentamicin) in 166 patients and included 2238 concentration measurements. The data were best described by a two-compartment model with creatinine clearance and height influencing aminoglycoside clearance, and height influencing volume of distribution. Between-subject and between-occasion variabilities in clearance were low, at 18% and 11%, respectively; between-subject variability was 12% for volume of distribution. Internal and external model validations were satisfactory. Multiple courses of therapy (ranging from 2 to 28 courses per patient) were not associated with any systematic changes in aminoglycoside clearance. Conclusions Height was a better descriptor of aminoglycoside pharmacokinetics than weight in adult patients with cystic fibrosis. No changes in clearance were observed over time, even in patients who had received multiple courses of therapy over several years. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
35. Rhabdomyolysis in MDMA Intoxication: A Rapid and Underestimated Killer. “Clean” Ecstasy, a Safe Party Drug?
- Author
-
Eede, Herve Vanden, Montenij, Leon J., Touw, Daan J., and Norris, Elizabeth M.
- Subjects
- *
RHABDOMYOLYSIS , *ECSTASY (Drug) , *DOSE-response relationship in poisons , *HYPERKALEMIA , *AMPHETAMINES , *BLOOD serum analysis - Abstract
Abstract: Background: Ecstasy is a popular drug among young adults. It is often thought to be safe. The dose of methylenedioxymethamphetamine (MDMA) in a tablet of Ecstasy varies greatly, and there is also a difference in individual response to a dose of MDMA. Objectives: To increase the awareness of potential mortality in MDMA use. Case Report: We report the case of a patient with a lethal intoxication after pure MDMA intoxication. The serum toxicology screening showed an elevated level of MDMA (1.5 mg/L) but no other amphetamines or other drugs. Conclusions: The cause of death was a rapidly evolving hyperkalemia due to rhabdomyolysis. There is still a need to educate the public about the dangers of this so-called “safe” party drug. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
36. Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
- Author
-
Scholtes, Rosalie A., Hesp, Anne C., Mosterd, Charlotte M., Geurts, Frank, Hoorn, Ewout J., Touw, Daan J., Krebber, Merle M., Joles, Jaap A., Heerspink, Hiddo J.L., and van Raalte, Daniël H.
- Subjects
- *
ANGIOTENSIN-receptor blockers , *EMPAGLIFLOZIN , *TYPE 2 diabetes , *ANGIOTENSIN receptors , *CROSSOVER trials , *HEMODYNAMICS , *KIDNEYS - Abstract
Keywords: angiotensin receptor blocker; diabetic kidney disease; sodium glucose cotransporter-2 inhibitor; type 2 diabetes mellitus EN angiotensin receptor blocker diabetic kidney disease sodium glucose cotransporter-2 inhibitor type 2 diabetes mellitus 1895 1897 3 12/15/22 20221213 NES 221213 Renin-angiotensin system (RAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors improve kidney outcomes in people with type 2 diabetes.[1] Lowering of glomerular pressure, clinically characterized by an acute estimated glomerular filtration rate (eGFR) decline, contributes to the kidney-protective properties of these drugs.[2] In all trials studying their kidney effects, SGLT2 inhibitors were introduced on top of standard of care, including RAS inhibition. We demonstrate that, compared with placebo, RAS and SGLT2 inhibition combination therapy induced a numerically greater reduction in mGFR and estimated glomerular pressure (Figure [I]) than either treatment alone. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
37. Effect of CYP2C19 *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
- Author
-
Hunfeld, Nicole G., Mathot, Ron A., Touw, Daan J., van Schaik, Ron H., Mulder, Paul G., Franck, Paul F., Kuipers, Ernst J., and Geus, William P.
- Subjects
- *
PHARMACODYNAMICS , *PROTON pump inhibitors , *ANTACIDS , *CAUCASIAN race , *CLINICAL pharmacology - Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • The influence of CYP2C19 on the kinetics and dynamics of omeprazole, lansoprazole and rabeprazole has been studied in Japanese subjects. • It has been suggested that subjects with *1/*1 genotype might need stronger acid suppression than *1/*2 and *2/*2 subjects. This suggestion comes from data in Japanese subjects and has not been confirmed in Caucasians. • Furthermore, a novel CYP2C19 mutation, *17, which mainly occurs in Caucasians has been discovered. This mutation has been associated with clinical failure, but its relevance for therapy with PPIs has not been studied yet. WHAT THIS STUDY ADDS • In this study, the influence of CYP2C19 on both the pharmacokinetics and dynamics in Caucasian subjects after single and repeated dosing has been investigated. • This is the first study showing that Caucasian subjects with *1/*1 and *1/*17 mutations need stronger acid-inhibition. In this study three proton pump inhibitors (omeprazole, lansoprazole and pantoprazole, in different doses) were studied of which pantoprazole had not been studied before in this setting, not even in Japanese. AIMS To investigate the impact of CYP2C19 mutations *2-*6 and *17 on acid-inhibition and pharmacokinetics of lansoprazole (L15), omeprazole (O10, O20) and pantoprazole (P40) in Caucasians. METHODS CYP2C19 genotyping for *2–*6 and *17 mutations was assessed in subjects who were H. pylori negative in two randomized crossover trials. The influence of CYP2C19 mutations on single and repeated administration of L15 and O10 (study A) and O20 and P40 (study B) was investigated. Pharmacokinetics and the cumulative percentage of time with intragastric pH above 4 (% > pH 4) were assessed on day 1 and 6. RESULTS For study A CYP2C19 genotyping found five *1/*1, four *1/*2, one *1/*17 and one *2/*17. For study B the results were six *1/*1, two *1/*2, six *1/*17, one *2/*2 and one *2/*17. For all PPIs AUC was highest in *2/*2 and lowest in *1/*17. On day 1, all PPIs significantly increased percentage >pH 4 compared with baseline. *1/*1 genotype showed no significant acid-inhibition after L15, O10 and O20. *1/*17 genotype showed no significant acid-inhibition after O20 and P40. *1/*2 genotype showed significant acid-inhibition after L15 and O10. On day 6, all four PPIs showed significantly increased acid-inhibition. *1/*1 and *1/*17 showed a significantly increased percentage > pH 4 after treatment with O20 and P40. However, in *1/*1 subjects percentage > pH 4 was not significantly increased after L15 and O10. *1/*2 genotype showed a significant acid-inhibitory effect after repeated dosing with L15 and O10. CONCLUSIONS Caucasian subjects with *1/*1 and *1/*17 genotype need stronger acid-suppression therapy, especially during the first days of treatment or with on-demand therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
38. Multi-infusion with integrated multiple pressure sensing allows earlier detection of line occlusions.
- Author
-
Doesburg, Frank, Oelen, Roy, Renes, Maurits H., Lourenço, Pedro M., Touw, Daan J., and Nijsten, Maarten W.
- Subjects
- *
ALGORITHMS , *INTRAVENOUS therapy , *PRESSURE sensors , *STANDARD deviations , *LOGISTIC regression analysis , *CLINICAL trial registries , *HERBAL teas - Abstract
Background: Occlusions of intravenous (IV) tubing can prevent vital and time-critical medication or solutions from being delivered into the bloodstream of patients receiving IV therapy. At low flow rates (≤ 1 ml/h) the alarm delay (time to an alert to the user) can be up to 2 h using conventional pressure threshold algorithms. In order to reduce alarm delays we developed and evaluated the performance of two new real-time occlusion detection algorithms and one co-occlusion detector that determines the correlation in trends in pressure changes for multiple pumps. Methods: Bench-tested experimental runs were recorded in triplicate at rates of 1, 2, 4, 8, 16, and 32 ml/h. Each run consisted of 10 min of non-occluded infusion followed by a period of occluded infusion of 10 min or until a conventional occlusion alarm at 400 mmHg occurred. The first algorithm based on binary logistic regression attempts to detect occlusions based on the pump's administration rate Q(t) and pressure sensor readings P(t). The second algorithm continuously monitored whether the actual variation in the pressure exceeded a threshold of 2 standard deviations (SD) above the baseline pressure. When a pump detected an occlusion using the SD algorithm, a third algorithm correlated the pressures of multiple pumps to detect the presence of a shared occlusion. The algorithms were evaluated using 6 bench-tested baseline single-pump occlusion scenarios, 9 single-pump validation scenarios and 7 multi-pump co-occlusion scenarios (i.e. with flow rates of 1 + 1, 1 + 2, 1 + 4, 1 + 8, 1 + 16, and 1 + 32 ml/h respectively). Alarm delay was the primary performance measure. Results: In the baseline single-pump occlusion scenarios, the overall mean ± SD alarm delay of the regression and SD algorithms were 1.8 ± 0.8 min and 0.4 ± 0.2 min, respectively. Compared to the delay of the conventional alarm this corresponds to a mean time reduction of 76% (P = 0.003) and 95% (P = 0.001), respectively. In the validation scenarios the overall mean ± SD alarm delay of the regression and SD algorithms were respectively 1.8 ± 1.6 min and 0.3 ± 0.2 min, corresponding to a mean time reduction of 77% and 95%. In the multi-pump scenarios a correlation > 0.8 between multiple pump pressures after initial occlusion detection by the SD algorithm had a mean ± SD alarm delay of 0.4 ± 0.2 min. In 2 out of the 9 validation scenarios an occlusion was not detected by the regression algorithm before a conventional occlusion alarm occurred. Otherwise no occlusions were missed. Conclusions: In single pumps, both the regression and SD algorithm considerably reduced alarm delay compared to conventional pressure limit-based detection. The SD algorithm appeared to be more robust than the regression algorithm. For multiple pumps the correlation algorithm reliably detected co-occlusions. The latter may be used to localize the segment of tubing in which the occlusion occurs. Trial registration Not applicable. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring.
- Author
-
Zijp, Tanja R., Izzah, Zamrotul, Åberg, Christoffer, Gan, C. Tji, Bakker, Stephan J. L., Touw, Daan J., and van Boven, Job F. M.
- Subjects
- *
CLINICAL drug trials , *SALIVA analysis , *ONLINE information services , *BIOMARKERS , *MEDICAL information storage & retrieval systems , *HAIR analysis , *SYSTEMATIC reviews , *DRUG monitoring , *PATIENT compliance , *LITERATURE reviews , *MEDLINE , *COLLECTION & preservation of biological specimens - Abstract
Introduction: Direct quantification of drug concentrations allows for medication adherence monitoring (MAM) and therapeutic drug monitoring (TDM). Multiple less invasive methods have been developed in recent years: dried blood spots (DBS), saliva, and hair analyses. Aim: To provide an overview of emerging drug quantification methods for MAM and TDM, focusing on the clinical validation of methods in patients prescribed chronic drug therapies. Methods: A scoping review was performed using a systematic search in three electronic databases covering the period 2000–2020. Screening and inclusion were performed by two independent reviewers in Rayyan. Data from the articles were aggregated in a REDCap database. The main outcome was clinical validity of methods based on study sample size, means of cross-validation, and method description. Outcomes were reported by matrix, therapeutic area and application (MAM and/or TDM). Results: A total of 4590 studies were identified and 175 articles were finally included; 57 on DBS, 66 on saliva and 55 on hair analyses. Most reports were in the fields of neurological diseases (37%), infectious diseases (31%), and transplantation (14%). An overview of clinical validation was generated of all measured drugs. A total of 62 drugs assays were applied for MAM and 131 for TDM. Conclusion: MAM and TDM are increasingly possible without traditional invasive blood sampling: the strengths and limitations of DBS, saliva, and hair differ, but all have potential for valid and more convenient drug monitoring. To strengthen the quality and comparability of future evidence, standardisation of the clinical validation of the methods is recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Type of proton‐pump inhibitor and risk of iron deficiency in kidney transplant recipients – results from the TransplantLines Biobank and Cohort Study.
- Author
-
Douwes, Rianne M., Vinke, Joanna Sophia J., Gomes‐Neto, António W., Ayerdem, Gizem, van Hassel, Gaston, Berger, Stefan P., Touw, Daan J., Blokzijl, Hans, Bakker, Stephan J. L., de Borst, Martin H., and Eisenga, Michele F.
- Subjects
- *
IRON deficiency , *KIDNEY transplantation , *COHORT analysis , *GASTRIC acid , *INTESTINAL absorption - Abstract
Summary: Proton‐pump inhibitors (PPIs) have been associated with iron deficiency (ID) in kidney transplant recipients (KTRs). Gastric acid plays a pivotal role in the intestinal absorption of non‐heme iron, but the pharmacodynamics of PPIs differs in potency of acid suppression. We hypothesized that the risk of ID might be lower in KTRs using a less potent PPI. In a cohort of 724 KTRs from the TransplantLines Biobank and Cohort Study (NCT03272841), PPI use was associated with ID [odds ratio (OR) 2.02; 95% CI 1.36–2.98]. Compared with no PPI use, the point estimate of the odds ratio for risk of ID for pantoprazole (OR 1.55; 95%CI 0.78–3.10) was lower than for esomeprazole and omeprazole (3.58; 95%CI 1.73–7.40 and 1.96; 95%CI 1.31–2.94, respectively). When comparing pantoprazole users with omeprazole users on an equipotent dose (≤20 omeprazole equivalents (OE)/day) omeprazole, but not pantoprazole was associated with ID, although the lack of a significant effect of pantoprazole on the risk of ID could be caused by a lack of power. Furthermore, risk of ID was higher among users of a high PPI dose (≥ 20 OE/day) and OE as continuous variable was also independently associated with ID, indicating that risk of ID is higher while using a more potent PPI. Further investigation seems warranted to confirm whether pantoprazole leads to less ID in KTRs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Multi-infusion with integrated multiple pressure sensing allows earlier detection of line occlusions.
- Author
-
Doesburg, Frank, Oelen, Roy, Renes, Maurits H., Lourenço, Pedro M., Touw, Daan J., and Nijsten, Maarten W.
- Subjects
- *
ALGORITHMS , *INTRAVENOUS therapy , *PRESSURE sensors , *STANDARD deviations , *LOGISTIC regression analysis , *CLINICAL trial registries , *HERBAL teas , *MEDICAL equipment reliability , *RESEARCH , *RESEARCH methodology , *PRESSURE , *MEDICAL cooperation , *EVALUATION research , *DRUG infusion pumps , *COMPARATIVE studies , *DRUGS - Abstract
Background: Occlusions of intravenous (IV) tubing can prevent vital and time-critical medication or solutions from being delivered into the bloodstream of patients receiving IV therapy. At low flow rates (≤ 1 ml/h) the alarm delay (time to an alert to the user) can be up to 2 h using conventional pressure threshold algorithms. In order to reduce alarm delays we developed and evaluated the performance of two new real-time occlusion detection algorithms and one co-occlusion detector that determines the correlation in trends in pressure changes for multiple pumps.Methods: Bench-tested experimental runs were recorded in triplicate at rates of 1, 2, 4, 8, 16, and 32 ml/h. Each run consisted of 10 min of non-occluded infusion followed by a period of occluded infusion of 10 min or until a conventional occlusion alarm at 400 mmHg occurred. The first algorithm based on binary logistic regression attempts to detect occlusions based on the pump's administration rate Q(t) and pressure sensor readings P(t). The second algorithm continuously monitored whether the actual variation in the pressure exceeded a threshold of 2 standard deviations (SD) above the baseline pressure. When a pump detected an occlusion using the SD algorithm, a third algorithm correlated the pressures of multiple pumps to detect the presence of a shared occlusion. The algorithms were evaluated using 6 bench-tested baseline single-pump occlusion scenarios, 9 single-pump validation scenarios and 7 multi-pump co-occlusion scenarios (i.e. with flow rates of 1 + 1, 1 + 2, 1 + 4, 1 + 8, 1 + 16, and 1 + 32 ml/h respectively). Alarm delay was the primary performance measure.Results: In the baseline single-pump occlusion scenarios, the overall mean ± SD alarm delay of the regression and SD algorithms were 1.8 ± 0.8 min and 0.4 ± 0.2 min, respectively. Compared to the delay of the conventional alarm this corresponds to a mean time reduction of 76% (P = 0.003) and 95% (P = 0.001), respectively. In the validation scenarios the overall mean ± SD alarm delay of the regression and SD algorithms were respectively 1.8 ± 1.6 min and 0.3 ± 0.2 min, corresponding to a mean time reduction of 77% and 95%. In the multi-pump scenarios a correlation > 0.8 between multiple pump pressures after initial occlusion detection by the SD algorithm had a mean ± SD alarm delay of 0.4 ± 0.2 min. In 2 out of the 9 validation scenarios an occlusion was not detected by the regression algorithm before a conventional occlusion alarm occurred. Otherwise no occlusions were missed.Conclusions: In single pumps, both the regression and SD algorithm considerably reduced alarm delay compared to conventional pressure limit-based detection. The SD algorithm appeared to be more robust than the regression algorithm. For multiple pumps the correlation algorithm reliably detected co-occlusions. The latter may be used to localize the segment of tubing in which the occlusion occurs. Trial registration Not applicable. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
42. Ganciclovir therapeutic drug monitoring in transplant recipients.
- Author
-
Märtson, Anne-Grete, Edwina, Angela E., Burgerhof, Johannes G. M., Berger, Stefan P., Joode, Anoek de, Damman, Kevin, Verschuuren, Erik A. M., Blokzijl, Hans, Bakker, Martijn, Span, Lambert F., Werf, Tjip S. van der, Touw, Daan J., Sturkenboom, Marieke G. G., Knoester, Marjolein, Alffenaar, Jan W. C., de Joode, Anoek, and van der Werf, Tjip S
- Subjects
- *
BLOOD coagulation factor VIII , *GANCICLOVIR , *STEM cell transplantation , *GLOMERULAR filtration rate , *HEMODIALYSIS patients , *TRANSPLANTATION of organs, tissues, etc. , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *DRUG monitoring , *RESEARCH funding , *LONGITUDINAL method - Abstract
Background: The use of (val)ganciclovir is complicated by toxicity, slow response to treatment and acquired resistance.Objectives: To evaluate a routine therapeutic drug monitoring (TDM) programme for ganciclovir in a transplant patient population.Methods: An observational study was performed in transplant recipients from June 2018 to February 2020. Dose adjustments were advised by the TDM pharmacist as part of clinical care. For prophylaxis, a trough concentration (Cmin) of 1-2 mg/L and an AUC24h of >50 mg·h/L were aimed for. For treatment, a Cmin of 2-4 mg/L and an AUC24h of 80-120 mg·h/L were aimed for.Results: Ninety-five solid organ and stem cell transplant patients were enrolled. Overall, 450 serum concentrations were measured; with a median of 3 (IQR = 2-6) per patient. The median Cmin and AUC24h in the treatment and prophylaxis groups were 2.0 mg/L and 90 mg·h/L and 0.9 mg/L and 67 mg·h/L, respectively. Significant intra- and inter-patient patient variability was observed. The majority of patients with an estimated glomerular filtration rate of more than 120 mL/min/1.73 m2 and patients on continuous veno-venous haemofiltration showed underexposure. The highest Cmin and AUC24h values were associated with the increase in liver function markers and decline in WBC count as compared with baseline.Conclusions: This study revealed that a standard weight and kidney function-based dosing regimen resulted in highly variable ganciclovir Cmin and under- and over-exposure were observed in patients on dialysis and in patients with increased renal function. Clearly there is a need to explore the impact of concentration-guided dose adjustments in a prospective study. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
43. Saliva-based linezolid monitoring on a mobile UV spectrophotometer.
- Author
-
Kim, Hannah Yejin, Ruiter, Evelien, Jongedijk, Erwin M, AK, Hemanth Kumar, Marais, Ben J, PK, Bhavani, Sawleshwarkar, Shailendra, Touw, Daan J, and Alffenaar, Jan-Willem
- Subjects
- *
LINEZOLID , *SPECTROPHOTOMETERS , *DRUG monitoring , *MATRIX effect , *LIQUID-liquid extraction , *ETHYL acetate , *SALT , *RESEARCH , *HIGH performance liquid chromatography , *SALIVA , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies - Abstract
Background: In TB, therapeutic drug monitoring (TDM) is recommended for linezolid; however, implementation is challenging in endemic settings. Non-invasive saliva sampling using a mobile assay would increase the feasibility of TDM.Objectives: To validate a linezolid saliva assay using a mobile UV spectrophotometer.Methods: The saliva assay was developed using NanoPhotometer NP80® and linezolid concentrations were quantified using second-order derivative spectroscopy. Sample preparation involved liquid-liquid extraction of saliva, using saturated sodium chloride and ethyl acetate at 1:1:3 (v/v/v). The assay was validated for accuracy, precision, selectivity, specificity, carry-over, matrix effect, stability and filters. Acceptance criteria were bias and coefficient of variation (CV) <15% for quality control (QC) samples and <20% for the lower limit of quantification (LLOQ).Results: Linezolid concentrations correlated with the amplitude between 250 and 270 nm on the second-order derivative spectra. The linezolid calibration curve was linear over the range of 3.0 to 25 mg/L (R2 = 0.99) and the LLOQ was 3.0 mg/L. Accuracy and precision were demonstrated with bias of -7.5% to 2.7% and CV ≤5.6%. The assay met the criteria for selectivity, matrix effect, carry-over, stability (tested up to 3 days) and use of filters (0.22 μM Millex®-GV and Millex®-GP). Specificity was tested with potential co-medications. Interferences from pyrazinamide, levofloxacin, moxifloxacin, rifampicin, abacavir, acetaminophen and trimethoprim were noted; however, with minimal clinical implications on linezolid dosing.Conclusions: We validated a UV spectrophotometric assay using non-invasive saliva sampling for linezolid. The next step is to demonstrate clinical feasibility and value to facilitate programmatic implementation of TDM. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania.
- Author
-
Mohamed, Sagal, Mvungi, Happiness C, Sariko, Margaretha, Rao, Prakruti, Mbelele, Peter, Jongedijk, Erwin M, Winkel, Claudia A J van, Touw, Daan J, Stroup, Suzanne, Alffenaar, Jan-Willem C, Mpagama, Stellah, Heysell, Scott K, and van Winkel, Claudia A J
- Subjects
- *
SALIVA , *RECEIVER operating characteristic curves , *ULTRAVIOLET spectrophotometry , *SPECTROPHOTOMETERS , *PHARMACOKINETICS , *ANTITUBERCULAR agents , *QUINOLONE antibacterial agents , *RIFAMPIN , *SPECTROPHOTOMETRY , *PROBABILITY theory - Abstract
Background: Early detection and correction of low fluoroquinolone exposure may improve treatment of MDR-TB.Objectives: To explore a recently developed portable, battery-powered, UV spectrophotometer for measuring levofloxacin in saliva of people treated for MDR-TB.Methods: Patients treated with levofloxacin as part of a regimen for MDR-TB in Northern Tanzania had serum and saliva collected concurrently at 1 and 4 h after 2 weeks of observed levofloxacin administration. Saliva levofloxacin concentrations were quantified in the field via spectrophotometry, while serum was analysed at a regional laboratory using HPLC. A Bayesian population pharmacokinetics model was used to estimate the area under the concentration-time curve (AUC0-24). Subtarget exposures of levofloxacin were defined by serum AUC0-24 <80 mg·h/L. The study was registered at Clinicaltrials.gov with clinical trial identifier NCT04124055.Results: Among 45 patients, 11 (25.6%) were women and 16 (37.2%) were living with HIV. Median AUC0-24 in serum was 140 (IQR = 102.4-179.09) mg·h/L and median AUC0-24 in saliva was 97.10 (IQR = 74.80-121.10) mg·h/L. A positive linear correlation was observed with serum and saliva AUC0-24, and a receiver operating characteristic curve constructed to detect serum AUC0-24 below 80 mg·h/L demonstrated excellent prediction [AUC 0.80 (95% CI = 0.62-0.94)]. Utilizing a saliva AUC0-24 cut-off of 91.6 mg·h/L, the assay was 88.9% sensitive and 69.4% specific in detecting subtarget serum AUC0-24 values, including identifying eight of nine patients below target.Conclusions: Portable UV spectrophotometry as a point-of-care screen for subtarget levofloxacin exposure was feasible. Use for triage to other investigation or personalized dosing strategy should be tested in a randomized study. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
45. Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.
- Author
-
Ariaans, Gerke, Tiersma, Jiske F., Evers, Bernardus, Gerding, Albert, Waaijer, Stijn J.H., Koster, Remco A., Touw, Daan J., Bakker, Barbara M., Reijngoud, Dirk-Jan, de Jong, Steven, and Jalving, Mathilde
- Subjects
- *
EVEROLIMUS , *PYRUVATE carboxylase , *TRIPLE-negative breast cancer , *BREAST cancer , *CANCER cell growth , *CANCER cells - Abstract
Reprogrammed metabolism is a hallmark of cancer, but notoriously difficult to target due to metabolic plasticity, especially in response to single metabolic interventions. Combining mTOR inhibitor everolimus and mitochondrial complex 1 inhibitor metformin results in metabolic synergy in in vitro models of triple-negative breast cancer. Here, we investigated whether the effect of this drug combination on tumor size is reflected in changes in tumor metabolism using [U-13C]glucose labeling in an MDA-MB-231 triple negative breast cancer xenograft model. The in vitro effects of everolimus and metformin treatment on oxidative phosphorylation and glycolysis reflected changes in 13C-labeling of metabolites in MDA-MB-231 cells. Treatment of MDA-MB-231 xenografts in SCID/Beige mice with everolimus resulted in slower tumor growth and reduced tumor size and tumor viability by 35%. Metformin treatment moderately inhibited tumor growth but did not enhance everolimus-induced effects. High serum levels of everolimus were reached, whereas levels of metformin were relatively low. Everolimus decreased TCA cycle metabolite labeling and inhibited pyruvate carboxylase activity. Metformin only caused a mild reduction in glycolytic metabolite labeling and did not affect pyruvate carboxylase activity or TCA cycle metabolite labeling. In conclusion, treatment with everolimus, but not metformin, decreased tumor size and viability. Furthermore, the efficacy of everolimus was reflected in reduced 13C-labeling of TCA cycle intermediates and reduced pyruvate carboxylase activity. By using in-depth analysis of drug-induced changes in glucose metabolism in combination with measurement of drug levels in tumor and plasma, effects of metabolically targeted drugs can be explained, and novel targets can be identified. [Display omitted] • Everolimus reduces pyruvate carboxylase activity in breast cancer • Metabolic activity in vitro differs greatly from that in vivo • Synergy between metformin and everolimus is absent in vivo • Metformin and everolimus serum and tumor levels explain in vivo effects [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. A mobile microvolume UV/visible light spectrophotometer for the measurement of levofloxacin in saliva.
- Author
-
Alffenaar, Jan-Willem C, Jongedijk, Erwin M, Winkel, Claudia A J van, Sariko, Margaretha, Heysell, Scott K, Mpagama, Stellah, Touw, Daan J, and van Winkel, Claudia A J
- Subjects
- *
SPECTROPHOTOMETERS , *VISIBLE spectra , *PHOTOMETRY , *SALIVA , *DRUG monitoring , *SPECTROPHOTOMETRY , *DRUG resistance , *RESEARCH , *HIGH performance liquid chromatography , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *LIGHT , *QUINOLONE antibacterial agents ,RESEARCH evaluation - Abstract
Introduction: Therapeutic drug monitoring (TDM) for personalized dosing of fluoroquinolones has been recommended to optimize efficacy and reduce acquired drug resistance in the treatment of MDR TB. Therefore, the aim of this study was to develop a simple, low-cost, robust assay for TDM using mobile UV/visible light (UV/VIS) spectrophotometry to quantify levofloxacin in human saliva at the point of care for TB endemic settings.Methods: All experiments were performed on a mobile UV/VIS spectrophotometer. The levofloxacin concentration was quantified by using the amplitude of the second-order spectrum between 300 and 400 nm of seven calibrators. The concentration of spiked samples was calculated from the spectrum amplitude using linear regression. The method was validated for selectivity, specificity, linearity, accuracy and precision. Drugs frequently co-administered were tested for interference.Results: The calibration curve was linear over a range of 2.5-50.0 mg/L for levofloxacin, with a correlation coefficient of 0.997. Calculated accuracy ranged from -5.2% to 2.4%. Overall precision ranged from 2.1% to 16.1%. Application of the Savitsky-Golay method reduced the effect of interferents on the quantitation of levofloxacin. Although rifampicin and pyrazinamide showed analytical interference at the lower limit of quantitation of levofloxacin concentrations, this interference had no implication on decisions regarding the levofloxacin dose.Conclusions: A simple UV/VIS spectrophotometric method to quantify levofloxacin in saliva using a mobile nanophotometer has been validated. This method can be evaluated in programmatic settings to identify patients with low levofloxacin drug exposure to trigger personalized dose adjustment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia.
- Author
-
Vellinga, Remco, Hannivoort, Laura N., Introna, Michele, Touw, Daan J., Absalom, Anthony R., Eleveld, Douglas J., and Struys, Michel M.R. F.
- Subjects
- *
PROPOFOL , *ANESTHESIA , *DRUG administration , *BLOOD sampling , *PHARMACOKINETICS , *BIOLOGICAL models , *OBESITY , *RESEARCH , *GENERAL anesthesia , *INTRAVENOUS therapy , *BODY weight , *AGE distribution , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *INTRAVENOUS anesthetics , *COMPARATIVE studies , *LONGITUDINAL method ,RESEARCH evaluation - Abstract
Background: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharmacodynamic (PK-PD) models can be used to facilitate drug administration. Existing models were developed using data from select populations, the use of which is, strictly speaking, limited to these populations. Recently a propofol PK-PD model was developed for a broad population range. The aim of the study was to prospectively validate this model in children, adults, older subjects, and obese adults undergoing general anaesthesia.Methods: The 25 subjects included in each of four groups were stratified by age and weight. Subjects received propofol through TCI with the Eleveld model, titrated to a bispectral index (BIS) of 40-60. Arterial blood samples were collected at 5, 10, 20, 30, 40, and 60 min after the start of propofol infusion, and every 30 min thereafter, to a maximum of 10 samples. BIS was recorded continuously. Predictive performance was assessed using the Varvel criteria.Results: For PK, the Eleveld model showed a bias < ±20% in children, adults, and obese adults, but a greater bias (-27%) in older subjects. Precision was <30% in all groups. For PD, the bias and wobble were <5 BIS units and the precision was close to 10 BIS units in all groups. Anaesthetists were able to achieve intraoperative BIS values of 40-60 using effect-site target concentrations about 85-140% of the age-adjusted Ce50.Conclusions: The Eleveld propofol PK-PD model showed predictive precision <30% for arterial plasma concentrations and BIS predictions with a low (population) bias when used in TCI in clinical anaesthesia practice. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
48. Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo Rat and Porcine Kidney Normothermic Machine Perfusion Model.
- Author
-
Huijink, Tobias M., Venema, Leonie H., Posma, Rene A., Vries, Nynke J., Westerkamp, Andrie C., Ottens, Petra J., Touw, Daan J., Nijsten, Maarten W., and Leuvenink, Henri G.D.
- Subjects
- *
REPERFUSION injury , *METFORMIN , *RATS , *HEAT shock proteins , *KIDNEYS , *ISCHEMIA - Abstract
Metformin may act renoprotective prior to kidney transplantation by reducing ischemia‐reperfusion injury (IRI). This study examined whether metformin preconditioning and postconditioning during ex vivo normothermic machine perfusion (NMP) of rat and porcine kidneys affect IRI. In the rat study, saline or 300 mg/kg metformin was administered orally twice on the day before nephrectomy. After 15 minutes of warm ischemia, kidneys were preserved with static cold storage for 24 hours. Thereafter, 90 minutes of NMP was performed with the addition of saline or metformin (30 or 300 mg/L). In the porcine study, after 30 minutes of warm ischemia, kidneys were preserved for 3 hours with oxygenated hypothermic machine perfusion. Subsequently, increasing doses of metformin were added during 4 hours of NMP. Metformin preconditioning of rat kidneys led to decreased injury perfusate biomarkers and reduced proteinuria. Postconditioning of rat kidneys resulted, dose‐dependently, in less tubular cell necrosis and vacuolation. Heat shock protein 70 expression was increased in metformin‐treated porcine kidneys. In all studies, creatinine clearance was not affected. In conclusion, both metformin preconditioning and postconditioning can be done safely and improved rat and porcine kidney quality. Because the effects are minor, it is unknown which strategy might result in improved organ quality after transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study.
- Author
-
Veenhof, Herman, Schouw, Hugo M., Besouw, Martine T. P., Touw, Daan J., and Gracchi, Valentina
- Subjects
- *
DRUG interactions , *DRUG monitoring , *TACROLIMUS , *GENE expression , *GLYCOPROTEINS , *GRAFT rejection , *IMMUNOSUPPRESSIVE agents , *LONGITUDINAL method , *STATISTICS , *TRANSPLANTATION of organs, tissues, etc. , *DATA analysis , *RETROSPECTIVE studies , *OXACILLIN , *DESCRIPTIVE statistics , *EVEROLIMUS , *CYTOCHROME P-450 , *PHARMACODYNAMICS - Abstract
Purpose: Tacrolimus and everolimus are widely used to prevent allograft rejection. Both are metabolized by the hepatic cytochrome P450 (CYP) enzyme CYP3A4 and are substrate for P-glycoprotein (P-gp). Drugs influencing the activity or expression of CYP enzymes and P-gp can cause clinically relevant changes in the metabolism of immunosuppressants. Several case reports have reported that flucloxacillin appeared to decrease levels of drugs metabolized by CYP3A4 and P-gp. The magnitude of this decrease has not been reported yet. Methods: In this single-center retrospective cohort study, we compared the tacrolimus and everolimus blood trough levels (corrected for the dose) before, during, and after flucloxacillin treatment in eleven transplant patients (tacrolimus n = 11 patients, everolimus n = 1 patient, flucloxacillin n = 11 patients). Results: The median tacrolimus blood trough level decreased by 37.5% (interquartile range, IQR 26.4–49.7%) during flucloxacillin treatment. After discontinuation of flucloxacillin, the tacrolimus blood trough levels increased by a median of 33.7% (IQR 22.5–51.4%). A Wilcoxon signed-rank test showed statistically significantly lower tacrolimus trough levels during treatment with flucloxacillin compared with before (p = 0.009) and after flucloxacillin treatment (p = 0.010). In the only available case with concomitant everolimus and flucloxacillin treatment, the same pattern was observed. Conclusions: Flucloxacillin decreases tacrolimus trough levels, possibly through a CYP3A4 and/or P-gp-inducing effect. It is strongly recommended to closely monitor tacrolimus and everolimus trough levels during flucloxacillin treatment and up to 2 weeks after discontinuation of flucloxacillin. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
50. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
- Author
-
van Bommel, Erik J. M., Geurts, Frank, Muskiet, Marcel H. A., Post, Adrian, Bakker, Stephan J. L., Danser, A. H. Jan, Touw, Daan J., van Berkel, Miranda, Kramer, Mark H. H., Nieuwdorp, Max, Ferrannini, Ele, Joles, Jaap A., Hoorn, Ewout J., and van Raalte, Danië l H.
- Subjects
- *
DAPAGLIFLOZIN , *TREATMENT effectiveness , *TYPE 2 diabetes , *KIDNEY physiology , *KREBS cycle , *SODIUM-glucose cotransporter 2 inhibitors , *SECONDARY analysis - Abstract
Sodium-glucose transporter (SGLT)2 inhibitors increase plasma magnesium and plasma phosphate and may cause ketoacidosis, but the contribution of improved glycemic control to these observations as well as effects on other electrolytes and acid-base parameters remain unknown. Therefore, our objective was to compare the effects of SGLT2 inhibitors dapagliflozin and sulfonylurea gliclazide on plasma electrolytes, urinary electrolyte excretion, and acid-base balance in people with Type 2 diabetes (T2D). We assessed the effects of dapagliflozin and gliclazide treatment on plasma electrolytes and bicarbonate, 24-hour urinary pH and excretions of electrolytes, ammonium, citrate, and sulfate in 44 metformin-treated people with T2D and preserved kidney function. Compared with gliclazide, dapagliflozin increased plasma chloride by 1.4 mmol/l (95% CI 0.4-2.4), plasmamagnesium by 0.03 mmol/l (95% CI 0.01-0.06), and plasma sulfate by 0.02 mmol/l (95% CI 0.01-0.04). Compared with baseline, dapagliflozin also significantly increased plasma phosphate, but the same trend was observed with gliclazide. From baseline to week 12, dapagliflozin increased the urinary excretion of citrate by 0.93 +- 1.72 mmol/day, acetoacetate by 48 µmol/day (IQR 17-138), and ß-hydroxybutyrate by 59 µmol/day (IQR 0-336), without disturbing acid-base balance. In conclusion, dapagliflozin increases plasma magnesium, chloride, and sulfate compared with gliclazide, while reaching similar glucose-lowering in people with T2D. Dapagliflozin also increases urinary ketone excretion without changing acid-base balance. Therefore, the increase in urinary citrate excretion by dapagliflozin may reflect an effect on cellular metabolism including the tricarboxylic acid cycle. This potentially contributes to kidney protection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.